Compass Therapeutics: Funding, Investors & Team (Oct 2026)
Compass Therapeutics, Inc. is a biopharmaceutical company focused on developing antibody therapies for solid tumors and blood cancers. They are using their unique technologies to identify potential antibody combinations that can be used in clinical trials. Their lead product, CTX-009, has completed a Phase 1 study and is now being tested in combination with chemotherapy for solid tumors. Their second product, CTX-471, is being studied in patients who have relapsed after treatment with other checkpoint inhibitors. Their third product, CTX-8371, is in early development stages. Compass Therapeutics was established in 2014 and is located in Boston, Massachusetts.
Compass Therapeutics has raised $120M across 1 funding round on record, the most recent an undisclosed round of $120M announced in Aug 2025.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Compass Therapeutics Company Profile and Key Stats
Latest funding round on record: Aug 2025.
Compass Therapeutics Funding Rounds
Compass Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Compass Therapeutics Funding Compared to Other Biotechnology Startups
Compass Therapeutics' latest round of $120M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Compass Therapeutics in Biotechnology and Boston
Companies Similar to Compass Therapeutics
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Compass Therapeutics Funding FAQs
What does Compass Therapeutics do?
Compass Therapeutics, Inc. is a biopharmaceutical company focused on developing antibody therapies for solid tumors and blood cancers. They are using their unique technologies to identify potential antibody combinations that can be used in clinical trials. Their lead product, CTX-009, has completed a Phase 1 study and is now being tested in combination with chemotherapy for solid tumors. Their second product, CTX-471, is being studied in patients who have relapsed after treatment with other checkpoint inhibitors. Their third product, CTX-8371, is in early development stages. Compass Therapeutics was established in 2014 and is located in Boston, Massachusetts.
How much funding has Compass Therapeutics raised?
Compass Therapeutics has raised $120M across 1 round on record. The most recent is an undisclosed round of $120M announced in Aug 2025.
When did Compass Therapeutics last raise funding?
Compass Therapeutics' most recent funding round on record is an undisclosed round of $120M, announced in Aug 2025.
Who founded Compass Therapeutics?
FundedIQ lists Thomas Schuetz (Founder) at Compass Therapeutics.
Where is Compass Therapeutics headquartered?
Compass Therapeutics is based in Boston, Massachusetts, United States.
How many employees does Compass Therapeutics have?
Compass Therapeutics is in the 11-50 employee band.
How does Compass Therapeutics' funding compare to other Biotechnology startups?
Compass Therapeutics' latest round of $120M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Compass Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Compass Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.